Abstracts tagged "Inflammation"

Abstract Number: 16 • 2012 ACR/ARHP Annual Meeting
Adenosine A_2A Receptor Diminishes Bone Destruction At Inflamed Sites, in Part, Via Downregulating Semaphorin4D-PlexinB1 Communication Between Osteoclasts and Osteoblasts
Aranzazu Mediero¹ and Bruce N. Cronstein², ¹Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, ²Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose: Communication between osteoclasts and osteoblasts is essential for bone homeostasis. Semaphorin4D (Sema4D), expressed on the surface of and secreted by osteoclasts, macrophages and T…
Abstract Number: 1619 • 2012 ACR/ARHP Annual Meeting
Quantification of Bone Marrow Edema by Using Magnetic Resonance Imaging for the Assessment of Neck Pain Only Marginally Reflects Clinical Evaluation in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
Xenofon Baraliakos¹, Frank Heldmann², Ravi Suppiah³, Fiona M. McQueen⁴ and Jürgen Braun², ¹Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, ⁴Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand
Background/Purpose: Despite the differences in the pathogenesis of rheumatoid arthritis (RA) and ankylosing spondylitis (AS), neck pain is a frequent clinical symptom in both diseases…
Abstract Number: 882 • 2012 ACR/ARHP Annual Meeting
Anti-Inflammatory Effects of Phosphodiesterase 4 Inhibition Are Mediated by Mitogen-Activated Protein Kinase Phosphatase-1
Riku Korhonen, Tuija Hömmö, Mirka Laavola, Tiina Keränen, Mari Hämäläinen and Eeva Moilanen, The Immunopharmacology Research Group, University of Tampere School of Medicine and Tampere University Hospital, Tampere, Finland
Background/Purpose: MAP kinase phosphatase-1 (MKP-1) is a nuclear tyrosine/threonine phosphatase that limits p38 MAP kinase activity. MKP-1 KO mice display excessive inflammatory response, and exhibit…
Abstract Number: 22 • 2012 ACR/ARHP Annual Meeting
Protective Properties of Conditioned Media From Adipose Stem Cells On Osteoarthritic Chondrocytes
Maria Isabel Guillén¹, Julia Platas¹, Vicente Mirabet², Miguel Angel Castejón³, Francisco Gomar⁴ and Maria Jose Alcaraz¹, ¹Pharmacology, University of Valencia, Burjasot, Valencia, Spain, ²Generalitat Valenciana, Valencia, Spain, ³De la Ribera University Hospital, Alzira, Spain, ⁴Surgery, University of Valencia and University Hospital, Valencia, Spain
Background/Purpose: Adipose-derived mesenchymal stem cells (ASC) exhibit a high potential for cell therapy and they might also act as a cellular source for supplying soluble…
Abstract Number: 1632 • 2012 ACR/ARHP Annual Meeting
Arhalofenate Is a Novel Dual-Acting Agent with Uricosuric and Anti-Inflammatory Properties
Yun-Jung Choi, Vanina Larroca, Annette Lucman, Vic Vicena, Noe Abarca, Tim Rantz, Brian E. Lavan and Charles A. McWherter, Biology, Metabolex, Inc., Hayward, CA
Background/Purpose: In most patients with gout, elevated serum urate is linked to excess uric acid reabsoprtion in the proximal renal tubule by anion transporters/exchangers, including…
Abstract Number: 872 • 2012 ACR/ARHP Annual Meeting
Monocyte Chemoattractant Protein-1 and Eotaxin Are Associated with Parameters of Cardiac Dysfunction in Juvenile Dermatomyositis
Thomas Schwartz¹, Ivar Sjaastad², Berit Flatø³, Maria Vistnes¹, Geir Christensen¹ and Helga Sanner³, ¹Institute for Experimental Medical Research, Institute for Clinical Medicine, University of Oslo, Oslo, Norway, ²Institute for Clinical Medicine, University of Oslo, Institute for Experimental Medical Research, Oslo University Hospital, Oslo, Norway, ³Department of Rheumatology, Oslo University Hospital, Institute for Clinical Medicine, University of Oslo, Oslo, Norway
Background/Purpose : Juvenile dermatomyositis (JDM) is a vasculopathic disease affecting not only skeletal muscle and skin, but other organs as well. Previously we have shown…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].